Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | Obecabtagene autoleucel |
Trade Name | Aucatzyl |
Synonyms | Obe-cel|AUTO1|AUTO-1|AUTO 1 |
Drug Descriptions |
Aucatzyl (obecabtagene autoleucel) comprises autologous T-lymphocytes engineered to express a chimeric antigen receptor (CAR) targeting CD19, which potentially decreases tumor growth (J Clin Oncol 41, no. 16_suppl (June 01, 2023) 7000). Aucatzyl (obecabtagene autoleucel) is FDA-approved for use in adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (FDA.gov). |
DrugClasses | CD19 Immune Cell Therapy 62 |
CAS Registry Number | NA |
NCIT ID | C172746 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
Obecabtagene autoleucel | Obecabtagene autoleucel | 0 | 1 |